Intrexon Corporation (NYSE:XON) COO Andrew J. Last acquired 2,000 shares of the firm’s stock in a transaction on Monday, August 14th. The stock was purchased at an average price of $19.99 per share, with a total value of $39,980.00. Following the acquisition, the chief operating officer now owns 2,000 shares of the company’s stock, valued at approximately $39,980. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Intrexon Corporation (NYSE XON) traded up 0.43% during midday trading on Tuesday, hitting $18.63. The stock had a trading volume of 1,527,522 shares. The company’s 50 day moving average price is $22.73 and its 200-day moving average price is $21.94. The stock’s market cap is $2.25 billion. Intrexon Corporation has a 52-week low of $17.70 and a 52-week high of $32.90.

Intrexon Corporation (NYSE:XON) last released its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.16) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. The firm had revenue of $54.40 million during the quarter, compared to analyst estimates of $57.17 million. Intrexon Corporation had a negative return on equity of 19.04% and a negative net margin of 60.63%. The business’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.42) EPS. Analysts forecast that Intrexon Corporation will post ($0.87) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This report was first reported by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was stolen and reposted in violation of international copyright & trademark law. The original version of this report can be read at https://www.watchlistnews.com/intrexon-corporation-xon-coo-andrew-j-last-buys-2000-shares/1492148.html.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Tower Research Capital LLC TRC raised its position in shares of Intrexon Corporation by 2,031.7% in the second quarter. Tower Research Capital LLC TRC now owns 5,180 shares of the biotechnology company’s stock valued at $125,000 after buying an additional 4,937 shares in the last quarter. Pacer Advisors Inc. raised its position in shares of Intrexon Corporation by 21.6% in the first quarter. Pacer Advisors Inc. now owns 7,352 shares of the biotechnology company’s stock valued at $146,000 after buying an additional 1,305 shares in the last quarter. SG Americas Securities LLC acquired a new position in shares of Intrexon Corporation during the first quarter valued at about $164,000. Federated Investors Inc. PA acquired a new position in shares of Intrexon Corporation during the second quarter valued at about $172,000. Finally, Cullinan Associates Inc. acquired a new position in shares of Intrexon Corporation during the second quarter valued at about $201,000. 84.52% of the stock is currently owned by institutional investors.

A number of equities analysts have issued reports on the company. BidaskClub upgraded Intrexon Corporation from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Northland Securities set a $30.00 price objective on Intrexon Corporation and gave the stock a “buy” rating in a report on Monday, August 7th. Finally, Zacks Investment Research upgraded Intrexon Corporation from a “hold” rating to a “buy” rating and set a $24.00 price objective for the company in a report on Tuesday, May 2nd. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and five have issued a buy rating to the company. Intrexon Corporation has an average rating of “Hold” and an average target price of $40.50.

About Intrexon Corporation

Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.

Insider Buying and Selling by Quarter for Intrexon Corporation (NYSE:XON)

Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.